CytomX Therapeutics announces 2024 company priorities

CytomX Therapeutics announced its 2024 company priorities and anticipated milestones for its wholly-owned and partnered pipeline. CX-904, EGFRxCD3 T-cell Engager: Initial Phase 1a dose escalation data is anticipated in the second half of 2024. The Phase 1a data will inform a potential decision during 2024 to initiate Phase 1b expansion cohorts in specific EGFR positive tumor types. The decision to potentially initiate Phase 1b expansion cohorts will be taken in conjunction with Amgen. CX-2051, Antibody Drug Conjugate targeting EpCAM: CX-2051 has demonstrated a wide predicted therapeutic index and strong preclinical activity and tolerability in multiple preclinical models, including colorectal cancer. An IND application has been filed for this program and clinical initiation in EpCAM expressing solid tumors is expected in the first half of 2024. CX-801, Interferon-alpha 2b: An IND application has been filed for this program. Phase 1 initiation for CX-801 as a monotherapy and in combination with checkpoint inhibition is expected in the first half of 2024. BMS-986288, Non-fucosylated CTLA-4-targeting Probody Therapeutic: The ongoing Phase 2 clinical evaluation of BMS-986288 includes proof of concept studies for microsatellite stable colorectal cancer and non-small cell lung cancer. Bristol Myers Squibb anticipates data from the study will be available in 20241. CytomX and Bristol Myers Squibb also continue to collaborate on multiple preclinical research programs.